
doi: 10.1042/cs051621s
pmid: 799569
1. In a cross-over study between hydrallazine and prazosin in fifteen patients, also treated with the β-receptor-blocking agent propranolol, 1 mg of prazosin was found to be equipotent with 30 mg of hydrallazine. 2. All patients were known to tolerate hydrallazine. In one patient prazosin treatment was discontinued because of severe headache. In four patients minor, non-persistent initial side effects were found. These might have been avoided by using a smaller starting dose. One patient fainted on the second day of prazosin treatment, probably from a micturition syncope. 3. Prazosin may be used as an alternative to hydrallazine. 4. The final status of prazosin as an anti-hypertensive drug is uncertain.
Clinical Trials as Topic, Hypertension, Quinazolines, Humans, Prazosin, Hydralazine, Propranolol
Clinical Trials as Topic, Hypertension, Quinazolines, Humans, Prazosin, Hydralazine, Propranolol
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
